PMC:6955813 / 2284-3437 JSONTXT

{"project":"2_test","denotations":[{"id":"31671579-21700881-56608597","span":{"begin":225,"end":226},"obj":"21700881"},{"id":"31671579-23162014-56608598","span":{"begin":238,"end":239},"obj":"23162014"},{"id":"31671579-29299748-56608599","span":{"begin":398,"end":399},"obj":"29299748"},{"id":"31671579-19468702-56608600","span":{"begin":573,"end":575},"obj":"19468702"},{"id":"31671579-23162014-56608601","span":{"begin":826,"end":827},"obj":"23162014"}],"text":"Many studies have assessed the role of CD14, especially at the molecular level, and established a link between the gene product and its single nucleotide polymorphisms (SNPs) with different complex diseases such as diabetes [6] and CVDs [7]. For example, the SNP rs2569190 in the promoter region of CD14 has been found to be implicated in coronary artery disease through changing protein levels [8,9]. Furthermore, the A allele has been reported to be functional and enhances CD14 expression, and thus the host sensitivity, for exogenous or endogenous lipopolysaccharides [10]. More importantly, soluble CD14 levels have shown strong, independent correlations with traditional cardio-metabolic risk factors and with subclinical measures of vascular disease (carotid wall thickness, ankle-brachial index, and body mass index) [7]. Based on all of the above, we hypothesize that rs2569190 in CD14 could be associated with CVD risk factors such as hypercholesterolemia and hypertension (HTN). Therefore, the goal of our study was to investigate the association of rs2569190 in CD14 with CVD risk factors in individuals from the general Lebanese population."}

{"project":"PubTator4TogoVar","denotations":[{"id":"10109","span":{"begin":877,"end":886},"obj":"SNP"},{"id":"10111","span":{"begin":1061,"end":1070},"obj":"SNP"},{"id":"10113","span":{"begin":263,"end":272},"obj":"SNP"}],"attributes":[{"id":"A10109","pred":"resolved_to","subj":"10109","obj":"tmVar:rs2569190;VariantGroup:3;CorrespondingGene:929;RS#:2569190;CorrespondingSpecies:9606"},{"id":"A10111","pred":"resolved_to","subj":"10111","obj":"tmVar:rs2569190;VariantGroup:3;CorrespondingGene:929;RS#:2569190;CorrespondingSpecies:9606"},{"id":"A10113","pred":"resolved_to","subj":"10113","obj":"tmVar:rs2569190;VariantGroup:3;CorrespondingGene:929;RS#:2569190;CorrespondingSpecies:9606"}],"text":"Many studies have assessed the role of CD14, especially at the molecular level, and established a link between the gene product and its single nucleotide polymorphisms (SNPs) with different complex diseases such as diabetes [6] and CVDs [7]. For example, the SNP rs2569190 in the promoter region of CD14 has been found to be implicated in coronary artery disease through changing protein levels [8,9]. Furthermore, the A allele has been reported to be functional and enhances CD14 expression, and thus the host sensitivity, for exogenous or endogenous lipopolysaccharides [10]. More importantly, soluble CD14 levels have shown strong, independent correlations with traditional cardio-metabolic risk factors and with subclinical measures of vascular disease (carotid wall thickness, ankle-brachial index, and body mass index) [7]. Based on all of the above, we hypothesize that rs2569190 in CD14 could be associated with CVD risk factors such as hypercholesterolemia and hypertension (HTN). Therefore, the goal of our study was to investigate the association of rs2569190 in CD14 with CVD risk factors in individuals from the general Lebanese population."}

{"project":"PubTatorOnTogoVar","denotations":[{"id":"24878","span":{"begin":877,"end":886},"obj":"SNP"},{"id":"24880","span":{"begin":1061,"end":1070},"obj":"SNP"},{"id":"24882","span":{"begin":263,"end":272},"obj":"SNP"},{"id":"T1","span":{"begin":877,"end":886},"obj":"SNP"},{"id":"T2","span":{"begin":1061,"end":1070},"obj":"SNP"},{"id":"T3","span":{"begin":263,"end":272},"obj":"SNP"}],"attributes":[{"id":"A24878","pred":"resolved_to","subj":"24878","obj":"tmVar:rs2569190;VariantGroup:3;CorrespondingGene:929;RS#:2569190;CorrespondingSpecies:9606"},{"id":"A24880","pred":"resolved_to","subj":"24880","obj":"tmVar:rs2569190;VariantGroup:3;CorrespondingGene:929;RS#:2569190;CorrespondingSpecies:9606"},{"id":"A24882","pred":"resolved_to","subj":"24882","obj":"tmVar:rs2569190;VariantGroup:3;CorrespondingGene:929;RS#:2569190;CorrespondingSpecies:9606"}],"text":"Many studies have assessed the role of CD14, especially at the molecular level, and established a link between the gene product and its single nucleotide polymorphisms (SNPs) with different complex diseases such as diabetes [6] and CVDs [7]. For example, the SNP rs2569190 in the promoter region of CD14 has been found to be implicated in coronary artery disease through changing protein levels [8,9]. Furthermore, the A allele has been reported to be functional and enhances CD14 expression, and thus the host sensitivity, for exogenous or endogenous lipopolysaccharides [10]. More importantly, soluble CD14 levels have shown strong, independent correlations with traditional cardio-metabolic risk factors and with subclinical measures of vascular disease (carotid wall thickness, ankle-brachial index, and body mass index) [7]. Based on all of the above, we hypothesize that rs2569190 in CD14 could be associated with CVD risk factors such as hypercholesterolemia and hypertension (HTN). Therefore, the goal of our study was to investigate the association of rs2569190 in CD14 with CVD risk factors in individuals from the general Lebanese population."}